Circulating tumour cells (CTCs) shed into blood from primary cancers include putative precursors that initiate distal metastases 1 . Although these cells are extraordinarily rare, they may identify cellular pathways contributing to the blood-borne dissemination of cancer. Here, we adapted a microfluidic device 2 for efficient capture of CTCs from an endogenous mouse pancreatic cancer model 3 and subjected CTCs to single-molecule RNA sequencing 4 , identifying Wnt2 as a candidate gene enriched in CTCs. Expression of WNT2 in pancreatic cancer cells suppresses anoikis, enhances anchorage-independent sphere formation, and increases metastatic propensity in vivo. This effect is correlated with fibronectin upregulation and suppressed by inhibition of MAP3K7 (also known as TAK1) kinase. In humans, formation of non-adherent tumour spheres by pancreatic cancer cells is associated with upregulation of multiple WNT genes, and pancreatic CTCs revealed enrichment for WNT signalling in 5 out of 11 cases. Thus, molecular analysis of CTCs may identify candidate therapeutic targets to prevent the distal spread of cancer.
We established the Hb CTC-Chip microfluidic capture platform 1 to isolate CTCs from blood samples of a genetically engineered mouse pancreatic cancer model 2 , comparing their expression profile to that of simultaneously collected primary tumour and metastatic ascites cells ( Fig. 1a and Supplementary Fig. 1 ). Captured cells were stained for epithelial cytokeratin (CK) and the leukocyte marker CD45, with CTCs scored as CK 1 /CD45 2 (Fig. 1b ). Eight control tumour-free mice had a median of 1.3 CK 1 /CD45 2 cells per 100 ml of blood (range, 0.2-5.6; mean 6 s.d., 1.8 6 1.7) under the selected imaging parameters. Applying a threshold of $ 6 cells per 100 ml, 7 out of 8 tumour-bearing mice were positive for CTCs (median, 31 cells per 100 ml; range, 2-547; mean 6 s.d., 115 6 188) ( Fig. 1b, c) . Most CTCs were captured as single cells, although clusters of 5 to 10 cells were seen in ,50% of mouse blood samples. The on-chip purity of captured CTCs ranged from 0.1-6%, due to non-specific binding (NSB) by leukocytes (Supplementary Table 1 ).
Given the minute amounts and variable purity of CTCs, we applied a sub-microgram RNA-based sequencing method using a singlemolecule 'next generation' platform 3 , to derive a digital gene expression (DGE) profile. We processed each blood sample through paired EPCAM-and mock IgG-functionalized Hb CTC-Chips, allowing digital subtraction of matched NSB leukocyte reads from each CTCenriched DGE profile. Using the DEGseq statistical model 5 applied to the MA-plot with a false discovery rate (FDR) of 0.10, we identified 361 transcripts in mouse MPANC-9 cells that were increased more than twofold in anti-EPCAM-versus IgG-chips, and absent in blood from non-tumour-bearing mice (Fig. 1d ). This CTC candidate gene set was then compared with DGE profiles of 12 mouse and 15 human primary pancreatic tumours, versus normal mouse and human pancreata 6 , yielding a set of 9 tumour-associated genes whose expression was markedly increased in CTCs (Supplementary Table 2 ). One of these, Wnt2, was found to be consistently enriched in pancreatic cancers in the Oncomine database, leading us to pursue this gene as a prototype CTC-enriched transcript. RNA sequencing of metastatic cells in the mouse ascites demonstrated enrichment for Wnt2. A second mouse, MPANC-10, also demonstrated Wnt2 expression in both CTCs and metastatic ascites cells. The lower number of Wnt2 messenger RNA reads in MPANC-10 cells was correlated with the fewer cytokeratin transcript reads, indicating that both transcripts track with the number of CTCs in the blood specimen ( Supplementary Table 3 ).
Given the absence of antibodies for cellular imaging of WNT2, we developed fluorescent RNA in-situ hybridization (RNA-ISH) to verify Wnt2 expression in CTCs ( Supplementary Figs 2 and 3 ). RNA-ISH analysis of CTCs using dual staining for Wnt2 and cytokeratin mRNAs identified Wnt2 transcripts in 64% of cytokeratin-expressing cells in 3 out of 4 mice. A comparable Wnt2 mRNA signal was observed in metastatic cells from ascites of mice bearing pancreatic tumours ( Fig. 1e ). In contrast, within primary tumour specimens, Wnt2 mRNA expression was only detectable in very small localized clusters of cells (1-5% of all cells) in 8 out of 14 primary tumour specimens ( Fig. 1f ). Histological analysis of rare Wnt2-positive cells within pancreatic ductal adenocarcinomas (PDACs) did not reveal any obvious distinction from other tumour cells. The small number of Wnt2-positive cells in primary tumour specimens was consistent with DGE analysis, which showed rare Wnt2 RNA reads in both mouse (8/12) and human (9/15) PDACs. Thus, Wnt2-positive cells are present within both CTC and metastatic ascites, and represent a rare subset of the primary tumour population.
To test the functional consequences of WNT2 expression in vivo, lentiviral constructs were introduced into NB508 PDAC cells, which lack detectable endogenous WNT2 expression ( Supplementary Fig. 4 ). Subcutaneous engraftment of green fluorescent protein (GFP)-tagged Wnt2-NB508 cells produced significantly more lung metastases in nude mice, compared with vector-transduced cells, despite the larger size of vector-expressing primary tumours (n 5 8, P , 0.05) ( Fig. 2a and Supplementary Fig. 4 ). EPCAM-captured CTCs showed a modest increase in numbers in mice bearing WNT2-expressing tumours, but this did not reach statistical significance (P 5 0.25, Fig. 2b ), even after normalization for the smaller size of WNT2-expressing tumours (P 5 0.17, Supplementary Fig. 4 ). Thus, WNT2 expression may increase the metastatic potential of circulating cancer cells, without markedly increasing their generation from primary tumours. Consistent with this hypothesis, direct intravascular inoculation of cells into the tail vein of syngeneic mice, which bypasses the vascular invasion step, showed a marked increase in lung metastases for Wnt2-NB508 cells (5/6 Wnt2transduced versus 0/6 vector, P , 0.05) ( Fig. 2c and Supplementary  Fig. 4 ). Modelling the effects of ectopic WNT2 expression on NB508 PDAC cells grown in vitro showed marked enhancement of anchorageindependent growth, without affecting cellular proliferation, migration or invasion assayed under standard conditions (Supplementary Figs 5, 6) . Tumour sphere formation under non-adherent conditions in serum-free media supplemented with growth factors 7, 8 was markedly increased by WNT2 expression, with respect to sphere numbers (P , 0.05) and size (P , 0.005) ( Fig. 2d and Supplementary Fig. 7) . Anoikis, the induction of apoptosis in epithelial cells resulting from loss of basement membrane attachment, was attenuated following WNT2 expression in NB508 cells ( Fig. 2e ). Resistance to anoikis is thought to be essential for epithelial cell survival in the bloodstream, and epithelial to mesenchymal transition (EMT) has been postulated to mediate this effect. We therefore tested for induction of characteristic mesenchymal markers by WNT2 at both RNA and protein levels, by DGE analysis and western blotting, respectively. Among classical EMT markers, we only detected induction of fibronectin (FN1), an extracellular protein implicated in cell-matrix interactions and cellular survival signals ( Fig. 2e and Supplementary Figs 6, 8 ). Short hairpin RNA-mediated knockdown of Fn1 suppressed the ability of ectopic WNT2 to enhance tumour sphere formation (n 5 6, P , 0.05, Fig. 2f ), indicating that Fn1 contributes to WNT2-mediated anoikis resistance. Two transcription factors, MYCN and the known FN1 regulator ETV4, were induced by WNT2, with their knockdown suppressing FN1 expression, indicating that they contribute to mediating the WNT2 effect ( Supplementary Fig. 9 ).
WNT2 may signal through either canonical (b-catenin/TCF dependent) or non-canonical pathways. Whereas canonical WNT signalling expression signatures have been developed, there are no such signatures for non-canonical WNT pathways. We therefore generated a customized non-canonical WNT signalling gene set (Supplementary Table 4 ) 9 and used this to interrogate the CTC DGE data. Significant enrichment was observed for components of the noncanonical WNT signalling pathway in mouse pancreatic CTCs, metastatic ascites cells, and Wnt2-NB508 cells grown under nonadherent sphere-forming conditions ( Supplementary Figs 10, 11 and Supplementary Table 5 ). Similar enrichment was noted for a WNTand TGF-b-driven signature 10 ( Supplementary Table 6 ).
No such enrichment was evident for signatures of canonical WNT signalling in CTCs and metastatic ascites cells, although Wnt2-NB508 cells showed a mild increase in canonical WNT signalling (Supplementary Table 6 , Supplementary Fig. 12 ).
We tested a panel of inhibitors of WNT-related pathways to identify small-molecule inhibitors capable of suppressing the WNT2 effect on anoikis. Among these, 5Z-7-oxozeaenol, an inhibitor of MAP3K7, also known as TAK1 (TGF-b activated kinase 1) 11 , was remarkable in completely abrogating WNT2-induced tumour spheres, without suppressing baseline sphere formation ( Fig. 3a and Supplementary  Figs 12, 13 ). 5Z-7-oxozeaenol also suppressed FN1 expression in Wnt2-NB508 cells (Fig. 3b ). To validate the effect of the TAK1 inhibitor in reversing the pro-survival phenotype conferred by WNT2, shRNA constructs targeting TAK1 were introduced into Wnt2-NB508 cells. TAK1 shRNAs suppressed FN1 expression in Wnt2-NB508 cells with an associated increase in cleaved caspase-3 ( Fig. 3c and Supplementary Fig. 9d ). Effective suppression of WNT2-induced tumour sphere formation was observed and correlated with the degree of TAK1 knockdown by the shRNA constructs ( Fig. 3d ). Consistent with these in vitro findings, the generation of metastases following tail vein inoculation of WNT2-expressing cells was suppressed as a function of shRNA knockdown of TAK1 ( Fig. 3e and Supplementary  Fig. 14) . Together, these results support the role of WNT2 in mediating metastasis-associated survival signals, which depend, at least in part, on a TAK1-FN1 signalling axis.
To extend our analyses to human pancreatic cancer, we captured CTCs from blood specimens of patients with metastatic pancreatic cancer using the Hb CTC-Chip and stained the cells with a combination of antibodies against cytokeratin and intracellular EPCAM residues ( Fig. 4a ). Under conditions optimized for human pancreatic CTC analysis, 10 healthy controls had a median 1.2 CK 1 EPCAM 1 / CD45 2 cells (range, 0 to 2.2; mean 6 s.d., 1.3 6 0.8). Of 15 patients with metastatic pancreatic cancer, 11 had CTC counts above threshold ($3 CK 1 EPCAM 1 /CK45 2 cells per ml), with a median 11 cells per ml (range, 1 to 57; mean 6 s.d., 18 6 18; on-chip median purity, 0.5%) ( Fig. 4b and Supplementary Table 7 ). We tested for WNT2 expression in human pancreatic CTCs using RNA-ISH identifying WNT2 transcripts in 23 out of 66 (35%) CK-positive CTCs from 2 out of 8 metastatic PDAC patients ( Fig. 4c ). To derive DGE profiles for human pancreatic CTCs, we followed the strategy defined for mouse CTC analyses, analysing blood specimens from 12 patients and 4 healthy controls using parallel anti-EPCAM versus mock IgG-functionalized Hb CTC-Chips, followed by low-quantity RNA-based single-molecule sequencing analysis. No individual WNT transcript was consistently enriched across all CTC-enriched populations (FDR 0.10), but among LETTER RESEARCH enrichment of non-canonical Wnt signalling pathway components and 8 (73%) showed enrichment for the WNT-and TGF-b-driven profile ( Supplementary Table 8 ). No such enrichment was present in 4 healthy controls or in one patient without detectable CTCs ( Supplementary Tables 9-11 ). WNT signalling and inhibition by suppression of MAP3K7 (TAK1). a, Suppression of Wnt2-induced, but not baseline, tumour sphere formation by NB508 cells, following treatment with 5Z-7-Oxozeaenol, a small molecule inhibitor of TAK1 (n 5 6). b, Immunoblot showing suppression of FN1 expression following treatment of non-adherent cultures of Vec-and Wnt2-NB508 cells with increasing concentrations of 5Z-7-Oxozeaenol. c, Immunoblot analysis of TAK1, FN1 and cleaved caspase 3 expression in Wnt2-NB508 cells following lentiviral infection with two different shRNAs targeting Tak1 or non-target (NT). d, Enumeration of tumour spheres formed by cells in c (n 5 6). e, Percentage of mice with detectable metastases by bioluminescence imaging for luciferase-producing tumour cells in mice 6 weeks following tail vein injection of Vec-NB508, Wnt2-NB508, and Wnt2-NB508 cells infected with three different shRNAs targeting Tak1 (n 5 12, 11, 14, 13 and 12, respectively). Immunoblot of TAK1 knockdown by shRNAs B6, B7, and B4 is shown (right). (mean 6 s.d., *P , 0.05)
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To test whether multiple WNT genes contribute to anoikis resistance in human pancreatic cancer, we measured expression of all known family members in six cell lines grown under non-adherent tumour sphere conditions. Five out of six cell lines showed upregulation of multiple WNT genes following shift from two-dimensional to threedimensional culture, an effect that was correlated with sensitivity to the TAK1 inhibitor and to TAK1 shRNA (Fig. 4d, e and Supplementary  Figs 15-17 , Supplementary Table 12 ). Thus, in human pancreatic cancer cells, the induction of multiple WNT family members seems to circumvent anoikis following loss of adherence, an effect suppressed by inhibition of TAK1.
In summary, we have applied microfluidic CTC isolation from a genetically engineered mouse model to generate an unbiased RNA sequencing profile for CTC-specific expression patterns. The cellular pathways activated during the haematogenous spread of human pancreatic cancer are likely to be complex, and our analysis is limited by technological hurdles inherent in the molecular characterization of partially purified CTC populations. Nonetheless, our results suggest that non-canonical WNT signalling pathways may contribute to metastasis in human pancreatic cancer. The effectiveness of TAK1 inhibition in suppressing this effect identifies a novel potential drug target for metastasis suppression.
METHODS SUMMARY
Mice with pancreatic cancer express Cre driven by Pdx1 or P48, along with LSL-Kras G12D , and Tp53 lox/1 or Tp53 lox/lox as previously described 3 . The mouse pancreatic tumour cell lines were generated from the resultant cancers. Mouse blood was obtained via cardiocentesis and was diluted 1:1 with PBS with 10 mM EDTA pH 7.4. Human blood for pancreatic CTC analysis was obtained after informed consent as per IRB protocol (05-300) at the Massachusetts General Hospital (MGH). Hb CTC-Chip production was as previously described 1 . Mouse Hb CTC-Chips were functionalized with biotinylated anti-mouse EPCAM (CD326) antibody (Biolegend 118204) or isotype control biotinylated Rat IgG2a (Biolegend 400504). Human Hb CTC-Chips were functionalized with biotinylated polyclonal goat anti-human EPCAM (R&D Systems BAF960) or control goat IgG antibody (R&D Systems BAF108). RNA was isolated from the devices using a modified protocol from the Qiagen RNeasy MinElute kit (Qiagen). Helicos singlemolecule sequencing was performed as previously described 4 . QuantiGene ViewRNA in-situ hybridization on Hb CTC-Chip was performed with a modified protocol from the manufacturer (Affymetrix). LETTER RESEARCH METHODS Mice, tumour tissues and cell lines. Mice with pancreatic cancer used in these experiments express Cre driven by Pdx1 or P48, LSL-Kras G12D , and Tp53 lox/1 or Tp53 lox/lox as previously described 2 . Normal B6/129, FVB, and Nu/Nu mice were purchased from Jackson Laboratory. For cardiocentesis, animals were sedated with isofluorane, the chest wall was sterilized with ethanol and a skin incision was made above the rib cage. To avoid potential contamination from cancer cells in the peritoneum, a 23-gauge needle was inserted through the intercostal muscle of the left chest into the heart and approximately 1 ml of blood was draw into a syringe primed with 100 ml of PBS with 10 mM EDTA pH 7.4 (Gibco). Animals were then euthanized per animal protocol guidelines. Pancreatic tumours and normal tissues were extracted and separated using flash-freezing with liquid nitrogen for RNA extraction and fixation with 4% paraformaldehyde (PFA) followed by paraffin embedding (FFPE) for RNA-ISH and histochemistry. Ascites if present were sterilely removed with a 23G needle syringe and cells were pelleted by centrifugation. Pelleted cells were flash-frozen in liquid nitrogen for RNA extraction. Cell lines generated from mouse tumours and human pancreatic cancer cell lines were grown in RPMI-1640 1 10% FBS 1 1% penicillin/ streptomycin (Gibco/Invitrogen).
Hb CTC-Chip production, preparation and blood processing. Hb CTC-Chips were manufactured on site at the MGH Cancer Center/BioMEMS Resource Facility, and chips were functionalized using biotinylated antibodies as previously described 1 . Mouse Hb CTC-Chips were functionalized with biotinylated anti-mouse EPCAM (CD326) antibody (Biolegend 118204) or isotype control biotinylated Rat IgG2a (Biolegend 400504). Human Hb CTC-Chips were functionalized with biotinylated polyclonal goat anti-human EPCAM (R&D Systems BAF960) or control goat IgG antibody (R&D Systems BAF108).
For mouse samples, approximately 1 ml of mouse blood was diluted 1:1 with PBS with 10 mM EDTA pH 7.4 and a total volume of 1 ml of diluted blood was processed on each Hb CTC-Chip, using a Harvard Apparatus volumetric syringe pump set at 1.5 ml h 21 . After processing the blood, devices were washed with PBS followed by analyses as described below.
Human blood specimens obtained for CTC analysis was obtained after informed consent, per IRB protocol (05-300) at the Massachusetts General Hospital (MGH). A maximum of 20 ml of blood were obtained at any given blood draw, using EDTA vacutainers. Blood specimens were processed through the Hb CTC-Chip within 4 h of blood draw. Approximately 3 ml of blood was processed through the Hb CTC-Chip, using the pressure controlled apparatus, at a target flow rate of 1.5 ml h 21 as previously described 2 . CTC staining and enumeration. Following blood processing, captured cells on the Hb CTC-Chip were fixed with 4% paraformaldehyde and washed with PBS. The fixed cells were then permeabilized with 1% NP40 in PBS, blocked with either 5% donkey serum (mouse samples) or 3% goat serum/2% BSA (human samples), and then immunostained with the relevant primary antibodies. Primary antibodies for the mouse CTC analyses were rabbit anti-wide spectrum cytokeratin (1:50, Abcam ab9377), chicken anti-GFP (1:1,000, Abcam ab13970) and goat anti-mouse CD45 (1:500, R&D systems AF114). Primary antibodies for the human CTC analyses were rabbit anti-wide spectrum cytokeratin (1:50, Abcam ab9377), rabbit anti-EPCAM (1:500, Abcam ab71916), and mouse IgG1 anti-CD45 (1:1,000, BD 55480). Secondary immunofluorescent-tagged antibodies were used for signal amplification. For the mouse, these were donkey anti-rabbit Alexa Fluor 594 (1:500, Invitrogen A-21207), donkey anti-chicken Dylight 488 (1:500, Jackson ImmunoResearch 703-486-155) and donkey anti-goat Alexa Fluor 488 (1:500, Invitrogen A-11055). For human, the secondary antibodies were goat anti-rabbit Alexa Fluor 594 (1:500, Invitrogen A-11012) and goat anti-mouse IgG1 Alexa Fluor 488 (1:500, Invitrogen A-21121). Nuclei were then stained with DAPI and the devices were washed with PBS and stored at 4 uC. The devices were imaged under 310 magnification using the BioView Ltd automated imaging system as well as an automated upright fluorescence microscope (Eclipse 90i, Nikon). Positive staining for cytokeratin or EPCAM, without CD45 staining, was required for scoring potential CTCs, which were then manually reviewed. Threshold and baseline signals were established using specimens from non-tumour-bearing mice or healthy human controls. RNA extraction and purification from the Hb CTC-Chip and from tissues. RNA from CTC-enriched cell populations was isolated from the devices using a modified protocol for the Qiagen RNeasy MinElute kit (Qiagen). Briefly, 375 ml of the RLT buffer was pipetted into the Hb CTC-Chip with mixing between the inlet and outlet of the device. The resulting RLT lysate was then loaded onto the Qiagen RNeasy MinElute column and RNA was purified per protocol. RNA was eluted in a total of , 10 ml RNase-free water.
To isolate RNA from fresh frozen tissues, the material was pulverized with a sterile pestle in a microfuge tube on dry ice. RNA from cell lines and fresh frozen tumour and normal tissues were all processed in the same manner. RNA was extracted using the TRIzol reagent (Invitrogen) per manufacturer's specifications. Single-molecule sequencing. Purified RNA was subjected to digital gene expression (DGE) sample prepping and analysed on the HeliScope Single Molecule Sequencer from Helicos BioSciences.
For mouse samples, a low quantity on surface RNA capture followed by complementary DNA synthesis and sequencing method was developed and used on RNA from EPCAM Hb CTC-Chip, IgG Hb CTC-Chip, primary tumour, and metastatic ascites. This method has been previously described 3 . Briefly, the purified RNA in RNase-free water was hybridized in 10-ml volume to Helicos poly(dT)-coated sequencing flow cell channels in 13 SSC, 0.05% SDS at 37 uC for 30 min. First-strand cDNA was synthesized with the SuperScript III firststrand cDNA synthesis kit (Invitrogen) using manufacturer's recommendations, except that no additional primers were added, and the incubation steps were modified as follows: 37 uC 15 min, and 55 uC 45 min. Subsequent to cDNA synthesis, hot water was passed through the channels to degrade and melt away the RNA strands. Guanine tailing was performed using terminal transferase, by adding 500 mM guanine in 20 ml volume in 13 TdT buffer, 2.5 mM CoCl 2 and 20 units terminal transferase per channel. The reaction took place at 37 uC for 30 min, followed by 39 blocking with 100 mM ddGTP and ddATP under the same reaction conditions. The 18-nucleotide poly-C primers were hybridized at 50 nM in 13 SSC, 0.05% SDS at 55 uC for 30 min, followed by step-wise 'fill' steps with 500 mM cytosine and adenine nucleotides with 5 units Klenow fragment (NEB) in 13 NEB2 buffer and 20 ml reaction volume per channel. The lock step was then performed with virtual terminator guanine and thymidine nucleotide analogues. Single-molecule sequencing by synthesis was then initiated using standard procedures 12 .
For human CTC samples, initial low quantity on surface methods did not have sufficient yield, so application of a low quantity RNA-seq method was used as previously described 13 . Briefly, the purified RNA in RNase-free water was converted to first-strand cDNA with the SuperScript III first-strand cDNA synthesis kit (Invitrogen) using random hexamers according to the manufacturer's recommendations. RNA was digested and single-stranded cDNA was purified using a combination of QIAquick nucleotide removal kit (Invitrogen) and ethanol precipitation with ammonium acetate and glycogen. Single-stranded cDNA was denatured and then a poly-A tail was added to the 39 end using terminal transferase (New England Biolabs). Tailed cDNAs were then hybridized to the sequencing flow cell followed by 'fill and lock' and subjected to single-molecule sequencing by synthesis. Bioinformatics. DGE: to compute digital gene expression (DGE) from the Helicos sequence data, we used the DGE pipeline of the HeliSphere 1.1.498.63 software (http://open.helicosbio.com) using the Human.Txome and Mouse.Txome (ftp:// ftp.helicosbio.com/pub/distribution) reference files 14 . We ignored DGE output corresponding to mitochondrial and ribosomal RNA and Helicos control spike-ins.
DEGSeq: DEGseq comparisons of DGE profiles were run using the DEGexp function of version 1.0.5 of the Bioconductor (http://www.bioconductor.org) DEGseq package. The 'method' argument was set to MARS for the MA-plot-based method with Random Sampling 5 and the threshold for statistical significance was a Benjamini-Hochberg q-value (that is, FDR estimate) of 10%.
hGSEA: we performed hypergeometric gene set enrichment analysis (hGSEA) as follows. To determine whether gene set A was enriched in gene set B, we used the hypergeometric distribution to test whether the overlap of A and B was larger than would be expected by chance had A and B been drawn randomly from all the genes quantified by the DGE. To account for multiple hypotheses testing, we applied the method of Benjamini and Hochberg to the p-values so generated for each analysis, yielding false discover rate (FDR) estimates. The odds ratio (OR) is the odds of a gene being in A given it is in B divided by the odds of that gene being in A given it is not in B. Gene sets evaluated were obtained from MSigDB (Broad Institute). QuantiGene ViewRNA in-situ hybridization on Hb CTC-Chip. Following blood processing, Hb CTC-Chips were fixed with 4% paraformaldehyde, washed with PBS and dehydrated with ethanol at increasing concentrations (50%, 70%, and 100%). Hb CTC-Chips were submerged in 100% ethanol at 220 uC for storage. Of note, mouse metastatic ascites fluid was also run on Hb CTC-Chips for RNA-ISH analysis. Before further analysis, cells were rehydrated using decreasing concentrations of ethanol (70% and 50%) and washed with PBS. ISH was performed using QuantiGene ViewRNA protocols. Hb CTC-Chip were permeabilized with Working Detergent Solution (Affymetrix), and digested with Protease (Affymetrix) at 1:2,000 dilution in PBS. The Hb CTC-Chips were hybridized for 3 h at 40 uC with custom-designed QuantiGene ViewRNA probes against genes of interest (mouse: Wnt2, Krt8 and Krt18; human: WNT2, KRT7, KRT8, KRT18, KRT19 and KRT23). Unbound probes were flushed out with Wash Buffer (Affymetrix) and Hb CTC-Chips were stored overnight at 4 uC in Storage Buffer (Affymetrix). The bound probes were amplified the following day through PreAmp (Affymetrix)
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hybridization for 1 h at 40 uC, followed by Amp (Affymetrix) hybridization for 1 h at 40 uC. Label Probes (Affymetrix) targeting the individual probe types were added for 1 h at 40 uC. Hb CTC-Chips were stained with DAPI, and images were taken using a Nikon 90i microscope. QuantiGene ViewRNA in-situ hybridization on FFPE tissue. Mouse tissue for FFPE was prepared per standard protocol by the MGH Clinical and Research Pathology Cores. ISH was performed using QuantiGene ViewRNA protocols. Five micrometre sections were cut, fixed in 10% formaldehyde (Fisher Scientific), deparaffinized, boiled in pre-treatment solution (Affymetrix) and digested with proteinase K (Affymetrix). Sections were hybridized for 3 h at 40 uC with custom-designed QuantiGene ViewRNA probes against Wnt2 and the control gene Ubc (Affymetrix). Bound probes were then amplified per protocol from Affymetrix using PreAmp and Amp molecules. Multiple Label Probe oligonucleotides conjugated to alkaline phosphatase (LP-AP Type 1) are then added and Fast Red Substrate is used to produce signal (red dots, Cy3 fluorescence). For two colour assays, an LP-AP type 6 probe is used with Fast Blue substrate (blue dots, Cy5 fluorescence) followed by LP-AP type 1 probe with Fast Red Substrate (red dots, Cy3 fluorescence) to produce a dual colorimetric and fluorescent signal. Wnt2 probes were used in type 1/Fast Red and pooled Krt8 and Krt18 were used in type 6/Fast Blue. Slides are then counterstained with haematoxylin. Serial sections were also subjected to haematoxylin and eosin staining per standard histology protocol to confirm the identity of cells in the region of RNA-ISH. Images were taken by a Nikon 90i scope with colour camera.
Constructs and viral infection. The mouse Wnt2 open reading frame was cloned into pENTRI plasmid as a BamHI-XhoI fragment. pWPI plasmid carrying Wnt2 open reading frame was generated by gateway cloning following the manufacturer's protocol (Invitrogen). Luciferase gene was expressed in pMSCV plasmid containing hygromycin selection marker. 7TFP construct (7xTcf-FFluc) used in TopFlash assay was from Addgene. pLKO shRNAs targeting the mouse Fn1 and Tak1 were from the RNAi consortium at the Broad Institute. Control shRNA constructs for Luciferase (SHC007, target sequences -GCGCGATAGCGCTAAT AATTT) and non-target (SHC016, target sequences -CGCTGAGTACTTCGAA ATGTC) were purchased from Sigma. Target sequences for Fn1: 59-GCCTAGA AATACCTTTCTCTT-39; for Tak1: B4 59-AGGCAAAGCAACAGAGTGAAT-39; B7 59-TCTGAGAGGAAGGCTTTCATT-39; B6 59-CAGCCCTAGTGTCAGAA TGAT-39; for human TAK1: 59-GACACACATGACCAATAACAA-39. Vesicular stomatitis virus glycoprotein-pseudotyped retroviruses or lentiviruses were generated using 293T cells as packaging cell lines following protocols described in the RNAi Consortium (Broad Institute). NB508 cells were infected with pWPI virus followed by GFP-positive cell sorting. pMSCV-luciferase was introduced into the cells and followed by 200 mg ml 21 hygromycin B selection. Cells transduced with pLKO shRNA virus were selected with 2 mg ml 21 puromycin. On-target plus siRNA constructs were purchased from Dharmacon and transfected into cells with Lipofectamine RNAiMax (Invitrogen). Target sequences for MYCN (L-058793-01): CCGGUGAACAAGCGAGAGA; UCGAAUUGGGCUACGGAGA; GAGGAU ACCUUGAGCGACU; UCUAACAACAAGGCGGUAA; ETV4 (L-048237-01): GGUCAGAGCUCCACUAUCC; UGAUCAAACAGGAGCGCAC; GAUACUU GGACCAGCGAGU; GAAAUGGGAGCUUGGGCGA; non-target (D-001810-10-20): UGGUUUACAUGUCGACUAA; UGGUUUACAUGUUGUGUGA; UGGUUUACAUGUUUUCUGA; UGGUUUACAUGUUUUCCUA. Tumorigenicity and experimental metastasis assays. The animal protocol was approved by the MGH Subcommittee on Research Animal Care. Six-week-old Nu/Nu mice were anesthetized by isofluorane, 1 3 10 6 NB508 cells expressing vector, or WNT2 in 100 ml of PBS were injected subcutaneously on the right flank of the mice. Primary tumours, CTCs and lungs were sampled after 2 weeks. Six to 8-week old FVB mice were used for tail vein injection. NB508 cells (5 3 10 4 ) expressing luciferase and vector, or WNT2 in 100 ml of PBS were injected into lateral tail vein of the mice. Tumour formation in the lung was monitored weekly by bioluminescence using IVIS Lumina II (Caliper Life Science). Mice were euthanized after 6 weeks and lungs were sampled. Comparison between groups was performed using t-test. Tumour sphere assay. Cells were plated as single-cell suspension in ultralow attachment 6-well or 96-well plates (Corning) and grown in RPMI medium (serum free) supplemented with 20 ml ml 21 B27 (Invitrogen), 20 ng ml 21 EGF and 20 ng ml 21 bFGF. Fresh media (1 ml or 30 ml) was added every 3 days. Tumour spheres were counted and photographed at day 10. Inhibitors were purchased from Sigma and used at 1 mM (for mouse cell lines) and 0.3, 1 and 3 mM (for human cell lines) (5Z-7-Oxozeaenol), 1.8 mM (IWR1), and 1.4 mM (Y-27632). For immunofluorescent staining, tumour spheres were deposited onto a microscope slide by cytospin (Shandon), fixed and stained. Comparison between groups was performed using t-test analysis (number differences) or Wilcoxon analysis (size differences). Anoikis assay. Plates were coated with 10 ml of 20 mg ml 21 poly-HEMA (Sigma) and air-dried. Cells (2 3 10 6 ) were plated on the poly-HEMA-coated plates. Cells were collected at different time points and proteins extracted. Antibodies and immunoblot analysis. Antibodies used were against b-catenin (BD), activated b-catenin (Millipore), Fibronectin, WNT2 (Sigma), b-tubulin (Santa Cruz), and cleaved Caspase-3, p-TAK1 (Cell Signaling), and TAK1 (Cell Signaling). Cells were lysed in RIPA lysis buffer (20 mM Tris, pH 8/150 mM NaCl/ 10 mM NaF/0.1% SDS/1% Nonidet P-40/13 protease inhibitor mixture (Roche)). For conditioned media, Vec-NB508 or Wnt2-NB508 cells were seeded at 1 3 10 6 in regular growth media (10% FBS) for 2 days in culture, and culture medium was replaced with low-serum media (0.2% FBS). After 24 h, conditioned medium was collected and cell debris was removed by centrifugation. Proteins were concentrated using Amico Ultracel 30k column (Millipore) and resuspended in RIPA buffer to detect the WNT2 protein by immunoblot. Lysates were run on an SDS/4-15% polyacrylamide gel (Bio-Rad) and transferred onto PVDF membranes (Invitrogen), and immunoblots were visualized with a Western Lightning Plus chemiluminescence kit (PerkinElmer). For phospho-TAK1 level, 1mg of protein lysate was immunoprecipitated with TAK1 antibody (Bethyl Laboratories) and blotted with p-TAK1 antibody (Cell Signaling). SYTO60 assay. Cells were seeded in 96-well plates in standard growth media at 1,000 cells per well or serum-free media at 5,000 cells per well. Cells were fixed every day after plating and incubated with Syto60 red fluorescence nucleic acid staining (Invitrogen) at 1:8,000 dilution in 13 PBS for 30 min in the dark. Red fluorescence nucleic acid staining was measured using a plate reader (Molecular Probes). Transwell migration and invasion assays. Cells (5 3 10 4 ) were seeded on 8-mm pore size Transwell filters (Corning) in regular growth media or low-serum media (0.2% FBS). Invasion chambers coated with Matrigel (Corning) were used for invasion assays with cells plated in regular growth media. Two days after seeding, cells on top of the chamber were stripped off with cotton tips and cells on the bottom of the chambers were fixed in 4% PFA and stained with crystal violet. Real-time qRT-PCR. Total RNA (2 mg) was reverse transcribed using a cDNA synthesis kit (GE Healthcare). Real-time quantitative RT-PCR was performed using SYBR green in an ABI PRISM 7500 sequence detection system with 96block module and automation accessory (Applied Biosystems). Gapdh was used as an internal control gene. The primers used are shown below: Gapdh: 59-TGGTGAAGCAGGCATCTGAG-39 and 59-TGCTGTTGAAGTCGCAGGAG-39. Etv4: 59-CGACTCAGATGTCCCTGGAT-39 and 59-GGAATGGTCGAAGGGA TTTT-39. Mycn: 59-GATGAGGATGACGAGGAGGA-39 and 59-ACGCACAG TGATCGTGAAAG-39. Fn1: 59-GATAAATCAGCAGTGGGAACGG-39 and 59-CAAAGCAAGTCTCTTCAGGCTCAG-39. TOPflash assay. Vec or Wnt2-NB508 cells were infected with lentivirus carrying 7TFP construct and selected with puromycin. Cells were plated in 96-well plate at 5 3 10 3 cells per well. Small molecule reagents were added into media 1 day after plating and cells were imaged in the IVIS Lumina II (Caliper Life Science) the following day. Low quantity high throughput qRT-PCR. RNA was isolated from adherent monolayer cells and tumour spheres cultured in non-adherent plate using Qiagen RNeasy kit (Qiagen). Reverse transcription was carried out using 200 ng of RNA with SuperScript III (Invitrogen) per manufacturer's protocol. Pre-amplification of cDNA was done with 1.25 ml of cDNA using pooled 48 TaqMan Assays at a final concentration of 0.23 for each assay. The pre-amplification PCR was performed at one cycle 95 uC for 10 min, 14 cycles at 95 uC for 15 s and then 60 uC for 4 min. After pre-amplification PCR, the product was diluted 1:5 with dH 2 O and stored at 280 uC until needed. qPCR was carried out using the 48.48 dynamic array (Fluidigm Corporation) following the manufacturer's protocol.
